Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents (original) (raw)
Rudek MA, Bauer KS Jr, Lush RM III, et al.: Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003, 37:1369–1374. ArticleCASPubMed Google Scholar
Aklilu M, Kindler HL, Donehower RC, et al.: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003, 14:1270–1273. ArticleCASPubMed Google Scholar
Zhai S, Sausville EA, Senderowicz AM, et al.: Clinical pharmacology and pharmacogenetics of flavopiridol 1-h I.v. infusion in patients with refractory neoplasms. Anticancer Drugs 2003, 14:125–135. ArticleCASPubMed Google Scholar
Kouroukis CT, Belch A, Crump M, et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740–1745. ArticleCASPubMed Google Scholar
Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001, 276:31793–31799. This represents the first demonstration that flavopiridol blocks gene transcription by inhibiting CDK9/cyclin T (ie, P-TEFb). ArticleCASPubMed Google Scholar
de Azevedo WF Jr, Canduri F, da Silveira NJ: Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002, 293:566–571. ArticlePubMed Google Scholar
Lam LT, Pickeral OK, Peng AC, et al.: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001, 2:RESEARCH0041. ArticleCASPubMedPubMed Central Google Scholar
Sausville EA, Elsayed Y, Monga M, Kim G: Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol 2003, 43:199–231. ArticleCASPubMed Google Scholar
Decker RH, Dai Y, Grant S: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptormediated pathway. Cell Death Differ 2001, 8:715–724. ArticleCASPubMed Google Scholar
Kitada S, Zapata JM, Andreeff M, Reed JC: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine downregulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000, 96:393–397. CASPubMed Google Scholar
Achenbach TV, Muller R, Slater EP: Bcl-2 independence of flavopiridol-induced apoptosis: mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem 2000, 275:32089–32097. ArticleCASPubMed Google Scholar
Pepper C, Thomas A, Hoy T, et al.: Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001, 114:70–77. ArticleCASPubMed Google Scholar
Decker RH, Wang S, Dai Y, et al.: Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther 2002, 1:136–144. ArticleCASPubMed Google Scholar
Gojo I, Zhang B, Fenton RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and downregulation of Mcl-1. Clin Cancer Res 2002, 8:3527–3538. It was reported in this study that the antiapoptotic molecule Mcl-1 represents an important target for flavopiridol-induced apoptosis, and that flavopiridol downregulates Mcl-1 levels through inhibition of mRNA transcription. This work documents the direct relationship between flavopiridol-mediated transcriptional inhibition and cytotoxicity. CASPubMed Google Scholar
Ma Y, Cress WD, Haura EB: Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003, 2:73–81. CASPubMed Google Scholar
Grant S, Roberts JD: The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updates 2003, 6:15–26. ArticleCAS Google Scholar
Wall NR, O’Connor DS, Plescia J, et al.: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 2003, 63:230–235. CASPubMed Google Scholar
Wittmann S, Bali P, Donapaty S, et al.: Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003, 63:93–99. CASPubMed Google Scholar
Matranga CB, Shapiro GI: Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res 2002, 62:1707–1717. CASPubMed Google Scholar
Jung CP, Motwani MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001, 7:2527–2536. CASPubMed Google Scholar
Motwani M, Sirotnak FM, She Y, et al.: Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002, 62:3950–3955. CASPubMed Google Scholar
Li W, Fan J, Bertino JR: Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 2001, 61:2579–2582. CASPubMed Google Scholar
Karp JE, Ross DD, Yang W, et al.: Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial. Clin Cancer Res 2003, 9:307–315. CASPubMed Google Scholar
Schwartz GK, O’Reilly E, Ilson D, et al.: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002, 20:2157–2170. ArticleCASPubMed Google Scholar
Cartee L, Wang Z, Decker RH, et al.: The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res 2001, 61:2583–2591. CASPubMed Google Scholar
Rosato RR, Almenara JA, Cartee L, et al.: The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrateinduced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther 2002, 1:253–266. CASPubMed Google Scholar
Almenara J, Rosato R, Grant S: Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002, 16:1331–1343. ArticleCASPubMed Google Scholar
Cartee L, Smith R, Dai Y, et al.: Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factormediated extrinsic cell death pathways. Mol Pharmacol 2002, 61:1313–1321. ArticleCASPubMed Google Scholar
Kim DM, Koo SY, Jeon K, et al.: Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines. Cancer Res 2003, 63:621–626. CASPubMed Google Scholar
Yu C, Krystal G, Dent P, Grant S: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002, 8:2976–2984. CASPubMed Google Scholar
Wu K, Wang C, D’Amico M, et al.: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 2002, 1:695–706. CASPubMed Google Scholar
Dai Y, Rahmani M, Grant S: Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NFkappaB-dependent process. Oncogene 2003, 22:7108–7122. ArticleCASPubMed Google Scholar
Nakanishi T, Karp JE, Tan M, et al.: Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 2003, 9:3320–3328. CASPubMed Google Scholar
Sausville EA, Arbuck SG, Messmann R, et al.: Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001, 19:2319–2333. ArticleCASPubMed Google Scholar
Johnson LN, De Moliner E, Brown NR, et al.: Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol Ther 2002, 93:113–124. ArticleCASPubMed Google Scholar
Patel V, Lahusen T, Leethanakul C, et al.: Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1). Clin Cancer Res 2002, 8:3549–3560. CASPubMed Google Scholar
Yu Q, La Rose J, Zhang H, et al.: UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res 2002, 62:5743–5748. The authors initially identified chk1 as a critical target of UCN-01 and also elucidated the molecular mechanism underlying G2 checkpoint abrogation induced by UCN-01. In this study, it was further reported that chk2 might also be a UCN-01 target, and that inhibition of chk1 and chk2 by UCN-01 mediates S checkpoint abrogation. CASPubMed Google Scholar
Zhao B, Bower MJ, McDevitt PJ, et al.: Structural basis for Chk1 inhibition by UCN-01. J Biol Chem 2002, 277:46609–46615. ArticleCASPubMed Google Scholar
Kohn EA, Ruth ND, Brown MK, et al.: Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2002, 277:26553–26564. ArticleCASPubMed Google Scholar
Zhou XY, Wang X, Hu B, et al.: An ATM-independent S-phase checkpoint response involves CHK1 pathway. Cancer Res 2002, 62:1598–1603. CASPubMed Google Scholar
Heffernan TP, Simpson DA, Frank AR, et al.: An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Mol Cell Biol 2002, 22:8552–8561. ArticleCASPubMedPubMed Central Google Scholar
Sato S, Fujita N, Tsuruo T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002, 21:1727–1738. This study demonstrated that UCN-01 blocked the Akt survival pathway by inhibiting PDK1, a finding that may have implications for understanding the mechanism by which UCN-01 induces apoptosis. ArticleCASPubMed Google Scholar
Komander D, Kular GS, Bain J, et al.: Structural basis for UCN-01 (7-hydroxystaurosporine) specificity and PDK1 (3-phosphoinositide-dependent protein kinase-1) inhibition. Biochem J 2003, 375:255–262. ArticleCASPubMedPubMed Central Google Scholar
Wilson WH, Sorbara L, Figg WD, et al.: Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm. Clin Cancer Res 2000, 6:415–421. CASPubMed Google Scholar
Dai Y, Yu C, Singh V, et al.: Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001, 61:5106–5115. It was reported in this study that UCN-01 activated the MAP kinase pathway in human leukemia cells, and that blockade of this survival pathway dramatically potentiated cytotoxicity of UCN-01. These findings indicate that combining UCN-01 and other novel signal transduction modulators may represent a novel approach to the development of UCN-01 as an anticancer agent. CASPubMed Google Scholar
Dai Y, Landowski TH, Rosen ST, et al.: Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood 2002, 100:3333–3343. ArticleCASPubMed Google Scholar
Jia W, Yu C, Rahmani M, et al.: Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK-and AKT-related pathways. Blood 2003, 102:1824–1832. ArticleCASPubMed Google Scholar
McClue SJ, Blake D, Clarke R, et al.: In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002, 102:463–468. ArticleCASPubMed Google Scholar
Laurence V, Faivre S, Vera K, et al.: Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies [abstract]. Eur J Cancer 2002, 38:S49. Google Scholar
Kim KS, Kimball SD, Misra RN, et al.: Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002, 45:3905–3927. ArticleCASPubMed Google Scholar
Shapiro G, Lewis N, Bai S, et al.: A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors [abstract]. Proc ASCO 2003, 22:799. Google Scholar
Hoessel R, Leclerc S, Endicott JA, et al.: Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999, 1:60–67. ArticleCASPubMed Google Scholar
Davies TG, Bentley J, Arris CE, et al.: Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat Struct Biol 2002, 9:745–749. ArticleCASPubMed Google Scholar
Lane ME, Yu B, Rice A, et al.: A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001, 61:6170–6177. CASPubMed Google Scholar
Soni R, O’Reilly T, Furet P, et al.: Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 2001, 9:436–446. Article Google Scholar
Fry DW, Bedford DC, Harvey PH, et al.: Cell cycle and biochemical effects of PD 0183812: a potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 2001, 276:16617–16623. ArticleCASPubMed Google Scholar